Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.51 |
| ▸ | SORD | Q00796 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 5/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15341852 | 0.94 | ACHE (0.47) | ACHESORDKDM2BNR1H2NR1H3 | |
| SCHEMBL15341857 | 0.85 | SORD (0.41) | ACHESORDTLR9TLR8TLR7 | |
| SCHEMBL26141097 | 0.82 | SORD (0.47) | ACHESORDNR1H2NR1H3 | |
| SCHEMBL13384562 | 0.82 | SORD (0.47) | ACHESORDNR1H2NR1H3 | |
| SCHEMBL13384586 | 0.81 | SORD (0.46) | ACHESORDNR1H2NR1H3 | |
| SCHEMBL13384572 | 0.80 | ACHE (0.53) | ACHESORDNR1H2NR1H3 | |
| SCHEMBL12985842 | 0.79 | ACHE (0.51) | ACHESORDHRH3 | |
| SCHEMBL26818363 | 0.78 | ACHE (0.56) | ACHESORDNR1H2NR1H3 | |
| SCHEMBL15341759 | 0.78 | ACHE (0.54) | ACHESORDNR1H2NR1H3HRH3 | |
| SCHEMBL15341966 | 0.77 | ACHE (0.47) | ACHESORDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ACHE 4721/4885SORD 2270/4885TLR9 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.